One-year clinical experience on the use of Nintedanib in systemic sclerosis.
Luca MagnaniAmelia SpinellaSofia TestoniFederica LumettiChiara ScelfoLucia DardaniGianluigi BajocchiEnrico CliniCarlo SalvaraniDilia GiuggioliPublished in: Respirology case reports (2023)
We reviewed 11 patients with systemic sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non-specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5 mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated.
Keyphrases
- systemic sclerosis
- interstitial lung disease
- end stage renal disease
- idiopathic pulmonary fibrosis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- rheumatoid arthritis
- prognostic factors
- healthcare
- physical activity
- diffuse large b cell lymphoma
- cross sectional
- smoking cessation
- intensive care unit
- extracorporeal membrane oxygenation
- drug induced
- psychometric properties
- chronic lymphocytic leukemia